CCM
URGN icon

Cinctive Capital Management’s UroGen Pharma URGN Stock Holding History

Cinctive Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,991
Closed -$398K – 516
2025
Q4 		$398K Buy
+16,991
New +$369K 0.02% 340

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cinctive Capital Management's URGN Position: Q1 2026 in Review

Cinctive Capital Management sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 16,991 shares — an estimated $398K sold.

Cinctive Capital Management first reported a position in URGN in Q4 2025 and held it in 1 quarter. The position peaked at $398K in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Cinctive Capital Management reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 16,991 UroGen Pharma shares in Q1 2026, an estimated $398K.
  • Cinctive Capital Management first reported a position in UroGen Pharma in Q4 2025 and held it in 1 quarter.
  • Cinctive Capital Management's UroGen Pharma position peaked at $398K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.